WASHINGTON, D.C.âThe Association for the Accreditation of Human Research Protection Programs today announced that it has accredited four more research organizations-one each in the U.S., Canada, Korea, and Taiwan.
The newly accredited organizations are:
They join 18 other organizations in earning AAHRPP accreditation this year, bringing the total to 22 in 2017 and 251 accredited organizations overall. Of those, 49 are outside the U.S.
“This was a good year for AAHRPP accreditation and for the research participants that AAHRPP’s high standards help protect,” AAHRPP President and CEO Elyse I. Summers said.
“AAHRPP accreditation has long been recognized as the gold standard for research protections and as evidence of an organization’s commitment to high-quality, ethical research,” she added. “In an increasingly collaborative research enterprise, accreditation is more valuable than ever because it signals that an organization is a trusted partner.”
To earn accreditation, organizations must show that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research.
AAHRPP has accredited organizations across the United States and in Belgium, Brazil, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, South Africa, Taiwan and Thailand.
All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, 70 percent of U.S. medical colleges and 84 percent of the top National Institute of Health-funded academic medical centers are either AAHRPP accredited or have begun the accreditation process. NIH, the world’s largest public funder of research, has earned accreditation, as has Pfizer, Inc., the largest industry sponsor of clinical research.
About AAHRPP:
A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit www.aahrpp.org.
###
FOR MORE INFORMATION CONTACT:
Sarah Kiskaddon
Vice President, Global Development and Public Affairs
skiskaddon@aahrpp.org
(202) 783-1112
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.